BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 31883437)

  • 1. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
    van Es SC; van der Vegt B; Bensch F; Gerritse S; van Helden EJ; Boon E; Angus L; Overbosch J; Menke-van der Houven van Oordt CW; Verheul HM; van Herpen CML; Jager A; Oosting SF; de Vries EGE; Schröder CP
    Am J Surg Pathol; 2019 Oct; 43(10):1355-1360. PubMed ID: 31283631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
    Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
    Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of EDTA decalcification on estrogen receptor and progesterone receptor immunohistochemistry and HER2/neu fluorescence in situ hybridization in breast carcinoma.
    Washburn E; Tang X; Caruso C; Walls M; Han B
    Hum Pathol; 2021 Nov; 117():108-114. PubMed ID: 34461131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.
    Garuti A; Rocco I; Cirmena G; Chiaramondia M; Baccini P; Calabrese M; Palermo C; Friedman D; Zoppoli G; Ballestrero A
    Gynecol Oncol; 2014 Feb; 132(2):389-96. PubMed ID: 24269902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies.
    Ferguson J; Chamberlain P; Cramer HM; Wu HH
    Diagn Cytopathol; 2013 Jul; 41(7):575-81. PubMed ID: 22807465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
    Arnedos M; Nerurkar A; Osin P; A'Hern R; Smith IE; Dowsett M
    Ann Oncol; 2009 Dec; 20(12):1948-52. PubMed ID: 19570962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management.
    Francis IM; Altemaimi RA; Al-Ayadhy B; Alath P; Jaragh M; Mothafar FJ; Kapila K
    J Cytol; 2019; 36(2):94-100. PubMed ID: 30992644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.